Videos

The Long-Term Efficacy of Inebilizumab in NMOSD: Bruce Cree, MD, PhD, MAS

The professor of neurology at Mayo Clinic detailed ways to address social determinants of health and the gaps in care for patients with epilepsy.

Bruce Cree, MD, PhD, MAS, FAAN

April 24th 2021

Stroke Common Cause of Seizures, Inebilizumab Demonstrates Continued Benefits, Fremanezumab Safe in Patients With CV Risk

The clinical research director at the UCSF Multiple Sclerosis Center discussed the findings of the long-term open-label assessment of inebilizumab in neuromyelitis optica spectrum disorder.

NeurologyLive® Staff

April 24th 2021

Advantages of Fremanezumab Among CGRP Migraine Agents: Stephanie J. Nahas, MD

Neurology News Network for the week ending April 24, 2021.

Stephanie J. Nahas, MD

Genetic Testing and Diagnostic Delay in SMA

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University detailed the reasons fremanezumab stands out among a crowded migraine treatment landscape.

Crystal Proud, MD;Claudia Chiriboga, MD, MPH;Basil Darras, MD;Tom Crawford, MD ;Carolina Tesi Rocha, MD

Signs of Symptoms of Spinal Muscular Atrophy

Basil Darras, MD considers the impact of genetic testing for SMN1 deletion and SMN2 copy numbers in potential patients and discusses best practices to prevent diagnostic delay.

Crystal Proud, MD;Claudia Chiriboga, MD, MPH;Basil Darras, MD;Tom Crawford, MD ;Carolina Tesi Rocha, MD

Evaluating the Potential of Vultrisiran

Expert neurologist Carolina Tesi Rocha, MD reviews the signs and symptoms of SMA and their impact on the delay of developmental milestones in infants and toddlers.

John L. Berk, MD;P. James B. Dyck, MD;Michael J. Polydefkis, MD;Thomas H. Brannagan III, MD;Ronald Witteles, MD

Benefits of TTR Gene Silencers

Expert discussion on the recent topline results released for vutrisiran in the HELIOS-A trial.

John L. Berk, MD;P. James B. Dyck, MD;Michael J. Polydefkis, MD;Thomas H. Brannagan III, MD;Ronald Witteles, MD

Nipocalimab Shows Promise as Myasthenia Gravis Treatment: Jeffrey Guptill, MD, MS, MHS

Discussion on the role of TTR protein stabilizers and gene silencers for treating hereditary ATTR amyloidosis.

Jeffrey Guptill, MD, MS, MHS

Age Considerations: Patients With Nonactive MS Progression

The associate professor of neurology and neurologist at Duke University discussed the positive results of nipocalimab, a monoclonal antibody, in patients with myasthenia gravis.

Bruce Cree, MD, PhD, MAS, FAAN;Joseph R. Berger, MD;Kristen Krysko, MD;Fred D. Lublin, MD;Robert Fox, MD

Improving PAP Adherence in Younger Patients With OSA: William Noah, MD

Considerations regarding age in treatment decisions in patients with nonactive multiple sclerosis progression.

William Noah, MD

Atogepant Continues to Shine in Phase 3 ADVANCE Study: Lawrence Severt, MD, PhD

The director and founder of the Sleep Centers of Middle Tennessee discussed trends in positive airway pressure adherence that his center’s research has revealed.

Lawrence Severt, MD, PhD

Monitoring Response in Progressive MS

The director at AbbVie discussed a number of abstracts presented at AAN 2021 involving atogepant and its phase 3 ADVANCE study.

Bruce Cree, MD, PhD, MAS, FAAN;Joseph R. Berger, MD;Kristen Krysko, MD;Fred D. Lublin, MD;Robert Fox, MD

Applications of Telestroke and Teleneurology: Jason Poon, MD

Experts discuss how they monitor response to multiple sclerosis therapies and disease progression.

Jason Poon, MD

Comparing Sublingual and Subcutaneous Apomorphine

The neurologist at University of Utah discussed his research presented at AAN 2021 on telestroke’s accuracy of differentiating between acute ischemic stroke and mimics.

Laxman Bahroo, DO;Mindy K. Bixby, DO

Sublingual Apomorphine for Managing PD OFF Episodes

Mindy K. Bixby, DO and Laxman Bahroo, DO compare subcutaneous and sublingual apomorphine hydrochloride and discuss important factors to consider when selecting a formulation.

Laxman Bahroo, DO;Mindy K. Bixby, DO

The Safety Profiles of Therapies for Migraine

Experts in the management of Parkinson’s Disease OFF episodes provide insight into the sublingual formulation of apomorphine hydrochloride and discuss differences in its safety and efficacy profiles.

Philippa Cheetham, MBChB, MRCS, MD, FRCS;Jill Dehlin, RN;Jessica Ailani, MD

CGRP Inhibitors for Migraine

The potential connection between risk of dementia in patients treated with triptans for migraine as compared to the safety profiles of newer CGRP monoclonal antibodies.

Philippa Cheetham, MBChB, MRCS, MD, FRCS;Jill Dehlin, RN;Jessica Ailani, MD

Ublituximab and the Anti-CD20 Class in Multiple Sclerosis: Lawrence Steinman, MD

Jessica Ailani, MD, of MedStar Health, describes the mechanisms of action and indications for use of currently available CGRP inhibitors for migraine.

Lawrence Steinman, MD

Pimavanserin vs Off-Label Psychotics for Dementia-Related Psychosis: Clive Ballard, MD

The professor of neurology and Neurological Sciences, Pediatrics, and Genetics at Stanford Medicine discussed the ULTIMATE trial data presented at the 2021 AAN Annual Meeting.

Clive Ballard, MD

Counseling Patients on ALS Progression and Prognosis

The dean at the University of Exeter Medical School discussed the questions related to treating dementia-related psychosis and the options available.

Richard S. Bedlack, MD, PhD, MS;Ammar Al-Chalabi, MB, ChB, PhD;Jinsy A. Andrews, MD, MSc;Jeremy M. Schefner, MD, PhD

Diagnosing ALS: Common Mimics

Key opinion leaders ALS care comment on best practices when communicating with patients about the unpredictability of disease progression and prognosis.

Richard S. Bedlack, MD, PhD, MS;Ammar Al-Chalabi, MB, ChB, PhD;Jinsy A. Andrews, MD, MSc;Jeremy M. Schefner, MD, PhD

Disease-Modifying Therapy in Relapsing-Remitting MS

Panelists provide insight into what primary care physicians should consider when differentiating amyotrophic lateral sclerosis (ALS) from conditions with similar presentations.

Lauren B. Krupp, MD;Tanuja Chitnis, MD

Trends in Movement Disorder Research: Ihtsham ul Haq, MD, FAAN

Leaders in neurology provide insight into first-line disease-modifying therapies for relapsing-remitting multiple sclerosis, such as interferon or glatiramer acetate, and glucocorticoids for acute events.

Ihtsham ul Haq, MD, FAAN

Mitigating Disparities in Stroke Rehabilitation Care: Sana Somani, MD, MBBS

The chief of Movement Disorders Division at the University of Miami Miller School of Medicine discussed some of the recent focused efforts to uncover more about Parkinson disease and what is on the horizon.

Sana Somani, MD, MBBS

Patient’s Experience With Infusion Treatment for MS

The vascular neurology fellow at the University of Maryland Medical Center discussed strategies to improve stroke care efficiency in women and African Americans.

June Halper, MSN, MSCN;Mary Ann Picone, MD

Overview of Treatment Options for Progressive MS

Richard shares his experience receiving his infusion therapy for treatment of multiple sclerosis.

June Halper, MSN, MSCN;Mary Ann Picone, MD

Efficacy and Safety of Fremanezumab Further Displayed: Stephanie J. Nahas, MD

An expert neurologist discusses treatment options for progressive multiple sclerosis.

Stephanie J. Nahas, MD

Diagnosing MS: Criteria Used to Assess Lesions

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed 2 research projects she led presented at AAN 2021 on the efficacy and safety of fremanezumab.

Scott Newsome, DO, MSCS, FAAN;Patricia K. Coyle, MD;Robert Fox, MD;Clyde E. Markowitz, MD